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Background—The determinants of prognosis in patients with heart failure and preserved ejection fraction (HF-PEF) are
poorly documented.
Methods and Results—We evaluated data from 4128 patients in the I-PRESERVE trial (Irbesartan in Heart Failure with
Preserved Ejection Fraction Study). Multivariable Cox regression models were developed using 58 baseline
demographic, clinical, and biological variables to model the primary outcome of all-cause mortality or cardiovascular
hospitalization (1505 events), all-cause mortality (881 events), and HF death or hospitalization (716 events). Log
N-terminal pro–B-type natriuretic peptide, age, diabetes mellitus, and previous hospitalization for HF were the most
powerful factors associated with the primary outcome and with the HF composite. For all-cause mortality, log
N-terminal pro–B-type natriuretic peptide, age, diabetes mellitus, and left ventricular EF were the strongest independent
factors. Other independent factors associated with poor outcome included quality of life, a history of chronic obstructive
lung disease, log neutrophil count, heart rate, and estimated glomerular filtration rate. The models accurately stratified
the actual 3-year rate of outcomes from 8.1% to 59.9% (primary outcome) 2.7% to 36.5% (all-cause mortality), and
2.1% to 38.9% (HF composite) for the lowest to highest septiles of predicted risks.
Conclusions—In a large sample of elderly patients with HF and preserved EF enrolled in I-Preserve, simple clinical,
demographic, and biological variables were associated with outcome and identified subgroups at very high and very low
risk of events.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00095238. (Circ Heart Fail. 2011;4:27-35.)
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Recent surveys suggest that up to half of the patients withheart failure have a preserved left ventricular ejection
fraction (HF-PEF).1–3 Patients with HF-PEF are more com-
monly older women and a greater proportion have hyperten-
sive etiology.4–8 Although some reports suggested that mor-
tality in patients with HF-PEF was similar to that observed in
HF with low EF, most studies show that survival is better in
HF-PEF suggesting that a continuum of risk exists.1,5 This
condition is also associated with a high rate of rehospitaliza-
tion.1,5 In HF-PEF, identification of factors predicting mor-
tality or morbidity in HF-PEF remains largely unexplored, in
contrast to patients with HF and low EF. I-PRESERVE
(Irbesartan in Heart Failure with Preserved Ejection Fraction
Study) enrolled 4128 patients with HF-PEF. We used this
large database to assess the factors associated with outcome
in this condition and to quantify their individual power by the
development of prognostic models.
Clinical Perspective on p 35
Methods
The I-PRESERVE design and results have been described and
reported previously.9,10 In brief, patients enrolled in the trial were at
least 60 years of age and had HF symptoms and a left ventricular EF
of at least 45%. In addition, we required patients who had been
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hospitalized for HF during the previous 6 months to have current
New York Heart Association class II, III, or IV symptoms with
corroborative evidence. If they had not been hospitalized, they were
required to have ongoing class III or IV symptoms with
corroborative evidence.
Exclusion criteria have been detailed previously. Patients were
enrolled after informed consent was given at 293 sites in 25
countries.
End points used for the current analysis were (1) the primary
composite end point of the trial: all-cause mortality and protocol-
specified cardiovascular hospitalizations (HF, myocardial infarction,
stroke, and ventricular or atrial arrhythmias); (2) all-cause mortality;
and (3) the composite of HF death or hospitalization.
The Minnesota Living with Heart Failure score at baseline was used
to assess quality of life (QOL).11 The plasma level of N-terminal
pro–B-type natriuretic peptide (NT-proBNP) was measured at random
assignment and analyzed in a central laboratory (Esoterix, Belgium).
Values (expressed in pg/mL) were log-transformed.
Statistical Methods
To develop the final predictive models, we started from the entire list
of variables collected at the baseline visit in I-PRESERVE and a
variable for irbesartan versus placebo, excluding nonrandomized
medical therapy. With the remaining list of 58 variables, univariate
Cox proportional hazards models were fit individually for each of the
3 outcomes mentioned above. Association of each variable to the
outcomes was determined by comparing with an intercept only base
model. Any variable that had a 2 probability value 0.01 in any of
the models was considered as a candidate variable for the final
models.
The database for analysis included patients with all 58 variables,
which narrowed the study cohort from 4128 to 2563 patients. The
baseline characteristics of the subjects with full data and subjects
with missing data were examined for significant differences (Table
1). Based on Bonferroni-adjusted probability values, significant
differences were noted. Further, examination of the outcomes be-
tween the 2 cohorts by log-rank tests showed that those that had
missing data had a greater occurrence of primary events and
all-cause mortality.
Because there were significant differences between those with full
data and those with missing data and the number of subjects with
missing data was large, we examined multiple methods of imputation
and model building. The methods included (1) building and fitting
the model based on the full data cohort, (2) building the model based
on the full data cohort and fitting the model after imputation with
mean or median was used to fill in the missing data, (3) same as 2 but
with a regression based imputation after building the model, and (4)
building and fitting the model after a regression based imputation12
for the missing data. The major difference in method 4 compared
with methods 1 to 3 was to impute first and then build the model
based on all 4128 subjects. There were some differences in model
variables between method 4 and methods 1 to 3. All variables in
methods 1 to 3 entered into the method 4 model except for history of
myocardial infarction. With increased sample size, because imputa-
tion occurred before model building, there was more power to fit
more variables in the model. Additional variables that made it into
the models based on imputed data were sex, systolic blood pressure,
blood urea nitrogen, stroke or transient ischemic attack, pulmonary
congestion, body mass index, and atrial fibrillation. Most of these
entered after the variables from the methods 1 to 3 were already
entered. Each method’s model was fit, and Harrell C-statistic13 for
discrimination ability of models with censored data were calculated
and compared. There was very little variation in the C-statistics for
each model: Primary outcome ranged from 0.711 to 0.717; all-cause
mortality, 0.733 to 0.745; and HF composite, 0.765 to 0.777.
Because imputation by regression methods is more robust than by
mean or median, model-building based on full data does not depend
on imputation assumptions, and because the discrimination ability of
the different models are similar, we present the model that is built
based on the 2563 subjects with full data and then fit this model to
the total cohort after regression based imputation to replace the
missing baseline values (method 3).
Individually for each outcome, Cox proportional hazards models
were developed using a forward-only stepwise process with P0.01
as our threshold for entry into the model. Once the model was built,
forward, then backward, processes were run to see whether the same
models would be achieved, and they were the same. Final models
included the union of the variables that were in at least 1 of the
outcome’s model. Statistical strength of each variable in the final
models was quantified by the change in the log-likelihoods that
occurred by fitting a model with each variable individually dropped
from the full model. These quantities are 2 values, each with 1
degree of freedom.
-Coefficients for each continuous variable and outcome were
examined for linearity. This was done by splitting the variable into
groups by septiles or by relevant steps and plotting the hazard ratios
compared with a reference group on a log scale. Hazard ratios were
examined for ease of clinical interpretation. Those variables that
showed nonlinearity in the -coefficients were log-transformed
accordingly. For some variables in the model, linearity was seen only
after certain cut points: QOL50 on a 0 to 100 scale, EF60%, and
estimated glomerular filtration rate (GFR) 90 mL/min/1.73 m2 of
body surface area using the Modification of Diet in Renal Disease
(MDRD) formula.14 Values in regions where there was no risk nor
benefit were truncated to the cut-point, and these were then modeled
as continuous variables beyond the cut-point. In the supplemental
material, Figure A, B, C, and D show the log scale hazard ratio
relationship for EF, log NT-proBNP, estimated GFR, and age as
continuous variables for the 3 outcomes. Linearity was established
through logarithmic transformations for NT-proBNP and neutrophil
count. Binary and categorical variables were modeled with appro-
priate dummy variables.
Once models were finalized with the full data cohort, the effects of
missing data were examined. The majority of missing data was due
to QOL and NT-proBNP. Missing data accounted for 601 primary
events (364 all-cause mortality and 271 composite HF events) to be
left out of analysis. The effect of missing data on the model was
examined by imputing the missing data using a nonlinear regression
method and then fitting the model to the full cohort of patients. The
differences in estimates for each model were marginal, and therefore
we decided to include all events. We validated and presented the
final models as based on the full cohort with imputed data.
Risk scores were determined for each patient from the final
models and split into septiles of risk. A risk score is the linear
combination of the values for each risk factor and their correspond-
ing coefficient from the model. For ease in reporting, we multiplied
the risk scores by a factor of 10. An Efron bootstrap with 200
resamples was used to examine the model calibration by predicted
versus observed rates of event within 3 years by risk score septiles.
Kaplan–Meier curves of the septile groups were used to show the
ability to correctly separate populations of patients at risk. The
models’ discrimination abilities were assessed by Harrell C-statistic
for models with censored data,13 and internal validity was examined
by average C-statistic from 200 Efron bootstrap resamples.15
Results
Table 1 compares the baseline characteristics of the total
cohort, the model-building full data cohort, and the missing
data cohort. Based on Bonferroni-adjusted (32 tests) proba-
bility values, statistically and clinically significant differences
between the full data cohort and missing data cohort were
seen for left ventricular hypertrophy, hypertension etiology,
and anemia and history of hypertension, angina, percutaneous
coronary intervention or coronary artery bypass grafting, and
diabetes. Also, log-rank tests between the groups showed
significantly higher occurrence of the primary outcome and
all-cause mortality in those that needed imputed data. During
follow-up of the total cohort, 1505 primary end points
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Table 1. Clinical, Demographic, and Biological Baseline Characteristics and Rate of Events of the
Overall I-PRESERVE Population, of the Cohort of Patients With Full Data, and of the Cohort of Patients
With Missing Data
Characteristic
Full Cohort
(n4128)
Full Data
Cohort (n2563)
Missing Data
Cohort (n1656) P Value
Demographic
Age
Mean, y 727 717 727 0.2412
75 y, n (%) 1413 (34) 844 (33) 569 (36) 0.8496
Female sex, n (%) 2491 (60) 1562 (61) 929 (59) 1
Race, n (%) 0.2782
White 3859 (93) 2421 (94) 1438 (92)
Black 82 (2) 45 (2) 37 (2)
Asian 34 (1) 15 (1) 19 (1)
Other 152 (4) 81 (3) 71 (5)
Clinical
New York Heart Association class, n (%) 1
II 870 (21) 552 (22) 318 (20)
III 3144 (76) 1944 (76) 1200 (77)
IV 112 (3) 67 (3) 45 (3)
Heart rate, beats/min 7110 7110 7211 1
Blood pressure, mm Hg
Systolic 13615 13615 13615 1
Diastolic 799 799 789 0.0181
Body mass index 305 305 305 1
ECG findings, n (%)
Left ventricular hypertrophy 1260 (31) 840 (33) 420 (27) 0.0021
Left bundle-branch block 336 (8) 210 (8) 126 (8) 1
Atrial fibrillation or flutter 697 (17) 425 (17) 272 (17) 1
EF 0.590.09 0.590.09 0.590.09 1
Cause of HF, n (%)
Ischemia 1036 (25) 618 (24) 418 (27) 1
Hypertension 2622 (64) 1698 (66) 924 (59) 0.0001
Hospitalization for HF within previous 6 mo, n (%) 1816 (44) 1139 (44) 677 (43) 1
Medical history, n (%)
Hypertension 3650 (88) 2303 (90) 1347 (86) 0.0089
Angina symptoms 1652 (40) 1116 (44) 536 (34) 0.0001
Unstable angina 315 (8) 174 (7) 141 (9) 0.3478
Myocardial infarction 969 (23) 626 (24) 343 (22) 1
PCI or CABG 548 (13) 286 (11) 262 (17) 0.0001
Atrial fibrillation 1209 (29) 717 (28) 492 (31) 0.6228
Diabetes mellitus 1134 (27) 653 (25) 481 (31) 0.0089
Stroke or transient ischemic attack 399 (10) 233 (9) 166 (11) 1
QOL
Score on the Minnesota Living with HF Scale
Median 42 43 40 0.4121
Interquartile range 28–58 28–58 25–56
Laboratory measurements
Hemoglobin
Mean, g/dL 13.91.9 13.91.9 13.71.9 0.0262
Anemia, n (%) 514 (13) 293 (11) 221 (16) 0.0087
Creatinine, mg/dL 10.33 0.990.3 1.020.37 0.0887
(Continued)
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occurred, including 447 all-cause deaths and 1058 prespeci-
fied cardiovascular hospitalizations. Overall, there were 881
all-cause deaths and 716 HF events, including 125 fatal HF
events.
Table 2 shows the 10 strongest variables from univariate
analysis for the 3 outcomes. For each of the 3 outcomes, the
strongest associated factors were log plasma level of NT-
proBNP, age, renal function assessed either by blood urea
nitrogen or by estimated GFR and a history of a HF
hospitalization within 6 months before entry.
The rate of event increased progressively with increasing
age and log NT-proBNP. In contrast, a different pattern was
observed for EF and estimated GFR: For the former, the rate
of event increased for EF values below 60% and was constant
above 60% for all 3 outcomes, whereas for the latter, the rate
increased below 90 mL/min/1.73 m2 and was constant above
90 for all 3 outcomes (supplemental material: Figure A, B, C,
and D).
Table 3 shows the final models in descending order of
variable strength for each of the 3 modeled outcomes. Log
NT-proBNP was the strongest independent factor associated
with primary outcome and all-cause mortality and the second
strongest for HF composite. Previous HF hospitalization was
the strongest factor correlated with the HF composite. Age,
diabetes mellitus, heart rate, poor QOL, comorbidities such as
chronic obstructive pulmonary disease or impaired renal
function, EF, and previous myocardial infarction or ischemic
etiology were also identified as associated with poor out-
come. Overall, there was consistency across the 3 models as
to the most important factors associated with outcome.
Figure 1 illustrates the correlative power of the final
models: Kaplan–Meier curves for each outcome by septile of
the risk scores from the Cox models are shown. For each
outcome, patients in the 2 septiles with the higher risk score
had a particularly poor outcome.
Figure 2 shows model calibrations of the observed and
expected 3-year rates of primary outcome, all-cause mortal-
ity, and HF composite by septiles of risk. Predicted and
observed scores were well in line with only minor deviations
from equality in each outcome.
For the 3 outcomes, there was at least a 7-fold increase in
event rate for the highest septile of the risk score compared
with the lowest septile. The actual 3-year event rate in the
highest septile was 59.9% for the primary outcome, 36.5% for
all-cause mortality, and 38.9% for the HF composite. By
contrast, it was only 8.2%, 2.7%, and 2.1%, respectively, in
the lowest septile. The upper cutoffs of the septiles of risk
score are shown in Table 4.
The discrimination ability of the models was robust, with
Harrell C-statistics of 0.711 (primary outcome), 0.736 (all-
cause mortality), and 0.765 (HF composite), respectively.
Results from internal validation resampling showed no over-
inflation of the models’ discrimination ability, with averaged
C-indices of 0.711, 0.735, and 0.765, respectively.
Discussion
This study identified a set of clinical, demographic, and biolog-
ical variables that were strongly associated with cardiovascular
morbidity, all-cause death, and HF events in a large sample of
older patients with HF-PEF enrolled in I-PRESERVE.
Although NT-proBNP was moderately increased in the
overall population, a finding in line with other observa-
tions,16–19 baseline NT-proBNP was the most powerful inde-
pendent factor for the primary event and all-cause mortality
models. This observation has important clinical implications
for the identification of high-risk patients with this condition
and strongly supports using natriuretic peptides as an inclu-
sion criterion in future studies involving HF-PEF patients.
Age was another powerful factor associated with outcome
in our study. Older age has also been reported as a strong
prognostic factor in HF patients with low EF20–23 and in a
clinical trial spanning the full range of left ventricular
dysfunction.24 Because patients enrolled in I-PRESERVE
were, by protocol, 60 years of age or older, we were unable
to verify if there was a threshold value below which age had
little impact, as described in the CHARM program.24
The presence of diabetes mellitus was also associated with
a poor outcome. Although diabetes mellitus has been associ-
ated with poor outcome in patients with HF with low EF,24–26
a population in which ischemic cardiomyopathy predomi-
nates, our finding underlines the importance of this comor-
Table 1. Continued
Characteristic
Full Cohort
(n4128)
Full Data
Cohort (n2563)
Missing Data
Cohort (n1656) P Value
Estimated GFR
Mean, mL/min/1.73 m2 body surface area 7322 7322 7223 1
60 mL/min/1.73 m2, n (%) 1245 (31) 763 (30) 482 (33) 1
Potassium, mmol/L 4.40.47 4.40.46 4.40.5 1
NT-proBNP, pg/mL
Median 339 320 410 1
Interquartile range 134–963.5 126–928 153–1043
Outcome, n (%) Log-rank P
Primary outcome 1505 (36) 904 (35) 601 (38) 0.0068
All-cause mortality 881 (21) 517 (20) 364 (23) 0.0032
Composite HF outcome 716 (17) 445 (17) 271 (17) 0.6060
PCI indicates percutaneous coronary intervention; CABG, coronary artery bypass graft.
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bidity in a population consisting exclusively of HF-PEF with
lower overt ischemic heart disease.
The presence of a previous hospitalization for HF was
associated with a 2-fold increase in the rate of subsequent
HF events as it is in patients with HF with low EF.24 Our
observation confirms that patients with a recent admission for
HF, regardless of their EF, are a high-risk group for readmis-
sion and a population that should be targeted in designing
future trials on HF-PEF.
EF is a known predictor of outcome in HF with low EF.21,24
We found that EF was also associated with the primary
outcome and all-cause mortality in the I-PRESERVE popu-
lation, although the relationship was observed only when EF
was 60%. A weaker association was seen for the HF
outcome. Our results are similar to those of the CHARM
program, although their results found increased morbidity and
mortality risk for subjects with an EF45%.24 Heart rate was
identified as a factor associated with all-cause mortality and
with HF events. The relationship of heart rate to morbidity
and mortality has been reported previously27–31 in coronary
artery disease and in HF with low EF. It has been postulated
that increased heart rate is associated with increased oxygen
consumption and reduced myocardial oxygen supply result-
ing in myocardial energy imbalance. Our study suggests that
the relationship between heart rate and poor outcome is also
present in patients with HF-PEF.
Table 2. Strongest Univariate Association of Candidate Variables With Each Outcome
Variable Hazard Ratio (95% CI) 2 Value P Value
Ten strongest variables from univariate
analysis for primary composite
NT-proBNP: log, pg/mL 1.592 (1.525, 1.661) 458.6 0.0001
Age per 1-y increase 1.055 (1.048, 1.063) 209.9 0.0001
BUN: log 3.1 4.281 (3.535, 5.183) 172.6 0.0001
eGFR 90 by 1-unit decrease 1.019 (1.016, 1.022) 159.4 0.0001
Hosp for HF last 5 mo: Yes vs no 1.915 (1.729, 2.120) 157.6 0.0001
Atrial fibrillation: Yes vs no 1.926 (1.737, 2.136) 146.3 0.0001
Creatinine, mol/L 1.926 (1.771, 2.095) 135.5 0.0001
Neutrophil count: log 2.268 (1.945, 2.644) 110.1 0.0001
Albumin: log 2.261 (1.936, 2.639) 107 0.0001
EF 60% by 1% 1.048 (1.038, 1.058) 83.8 0.0001
Ten strongest variables from univariate
analysis for all-cause mortality
NT-proBNP: log, pg/mL 1.715 (1.621, 1.813) 363.7 0.0001
Age per 1-y increase 1.071 (1.061, 1.081) 197.1 0.0001
BUN: log 3.1 4.774 (3.792, 6.010) 134.6 0.0001
eGFR90 by 1-unit decrease 1.021 (1.017, 1.025) 118.4 0.0001
Creatinine, mol/L 2.080 (1.876, 2.305) 107 0.0001
EF 60% by 1% 1.059 (1.046, 1.073) 76.3 0.0001
Pulmonary congestion: Yes vs no 1.795 (1.569, 2.053) 72.6 0.0001
Atrial fibrillation Yes vs no 1.792 (1.567, 2.050) 68.9 0.0001
Neutrophil count: log 2.316 (1.898, 2.825) 68.9 0.0001
Albumin: log 2.292 (1.874, 2.803) 66.5 0.0001
Ten strongest variables from univariate
analysis for HF composite
NT-proBNP: log, pg/mL 1.735 (1.631, 1.846) 307.7 0.0001
Hosp for last 6 mo: Yes vs no 2.924 (2.502, 3.417) 196.9 0.0001
eGFR 90 by 1-unit decrease 1.026 (1022, 1.030) 145.9 0.0001
Atrial fibrillation: Yes vs no 2.517 (2.173, 2.915) 144.9 0.0001
BUN: log 3.1 5.847 (4.543, 7.525) 139.7 0.0001
Age per 1-y increase 1.065 (1.054, 1.076) 136.5 0.0001
Atrial fibrillation or flutter: Yes vs no 2.364 (2.013, 2.778) 95.7 0.0001
Creatinine, mol/L 2.053 (1.841, 2.289) 89.7 0.0001
Neutrophil count: log 2.508 (2.008, 3.131) 66 0.0001
Albumin: log 2.517 (2.012, 3.149) 65.3 0.0001
BUN indicates blood urea nitrogen; eGFR, estimated GFR (mL/mn/m2); and Hosp, hospitalization. Neutrophil count
is measured as 1000 cells/L and albumin as g/dL.
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The presence of lung disease was associated with a marked
increase in rate of event in the 3 models and particularly in the
rate of HF events. This is consistent with previous reports and
reflects the complexity of elderly patients with HF-PEF, who
often have multiple comorbidities and of their manage-
ment.32–34 Because by study design, severe pulmonary disease
was excluded, the impact of this comorbidity on outcome
could be even greater in an unselected population of HF-PEF.
Some factors such as renal function and prior myocardial
infarction were not as prominent as in other populations.
Renal function assessed by estimated GFR, univariately,
was strongly associated with poor outcome, but the 2 value
suggests that renal impairment only had a moderate impact
multivariately when the other variables were included. The
importance of renal dysfunction as a powerful marker of poor
outcome has been recognized in several studies or surveys of
patients with low EF as well as in HF-PEF patients.21,22,35–36
The lack of a stronger correlative value observed in the
present study may, in part, reflect the exclusion of patients
with severe renal impairment or anemia in I-PRESERVE.
Table 3. Final Model Summaries
Variable Hazard Ratio (95% CI) Coefficient Standard Error 2 Value P Value
Final model for primary composite
NT-proBNP: log, pg/mL 1.251 (1.201, 1.304) 0.224 0.021 114.5 0.0001
Age per 5-y increase 1.198 (1.151, 1.246) 0.180 0.020 79.3 0.0001
Hosp for HF last 6 mo 1.541 (1.386, 1.714) 0.433 0.054 64.5 0.0001
Diabetes mellitus 1.433 (1.285, 1.597) 0.359 0.056 40.4 0.0001
Neutrophils: log, pg/mL 1.458 (1.261, 1.686) 0.377 0.074 26.5 0.0001
EF per 5% decrease 60 1.135 (1.078, 1.195) 0.127 0.026 22.8 0.0001
COPD or asthma 1.413 (1.215, 1.643) 0.356 0.770 18.6 0.0001
GFR per 5-unit decrease 90 1.031 (1.015, 1.047) 0.031 0.008 15.2 0.0001
QOL per 5-unit increase 50 1.044 (1.021, 1.068) 0.043 0.012 13.3 0.0002
Ischemic etiology 1.199 (1.052, 1.367) 0.182 0.067 7.3 0.0066
Myocardial infarction 1.177 (0.849, 1.029) 0.163 0.069 5.6 0.0176
Heart rate per 5-bpm increase 1.021 (0.997, 1.045) 0.021 0.012 2.9 0.0869
Final model for all-cause mortality
NT-proBNP: log, pg/mL 1.341 (1.271, 1.415) 0.293 0.027 115.1 0.0001
Age per 5-y increase 1.277 (1.211, 1.345) 0.244 0.027 83.3 0.0001
Diabetes mellitus 1.482 (1.287, 1.706) 0.393 0.072 28.7 0.0001
EF per 5% decrease 60 1.174 (1.099, 1.253) 0.160 0.034 22.2 0.0001
Heart rate per 5-bpm increase 1.058 (1.027, 1.090) 0.056 0.015 13.2 0.0003
Neutrophils: log, pg/mL 1.387 (1.153, 1.668) 0.327 0.094 12.2 0.0005
Hosp for HF last 6 mo 1.225 (1.065, 1.410) 0.203 0.071 8.1 0.0043
QOL per 5-unit increase 50 1.045 (1.014, 1.076) 0.044 0.015 8 0.0047
COPD or asthma 1.320 (1.086, 1.604) 0.277 0.099 7.3 0.0068
GFR per 5-unit decrease 90 1.027 (1.007, 1.047) 0.026 0.010 6.8 0.0092
Ischemic etiology 1.192 (1.006, 1.413) 0.176 0.087 4 0.0442
Myocardial infarction 1.194 (1.003, 1.421) 0.178 0.089 3.9 0.0472
Final model for HF composite
Hosp for HF last 6 mo 2.235 (1.901, 2.627) 0.8 0.083 100.2 0.0001
NT-proBNP: log, pg/mL 1.274 (1.201, 1.352) 0.24 0.030 64.7 0.0001
Age per 5-y increase 1.216 (1.148, 1.288) 0.2 0.029 44.7 0.0001
Diabetes mellitus 1.688 (1.447, 1.969) 0.52 0.079 42.3 0.0001
GFR per 5-unit decrease 90 1.056 (1.033, 1.079) 0.05 0.011 32.2 0.0001
COPD or asthma 1.528 (1.244, 1.878) 0.42 0.105 14.9 0.0001
Neutrophils: log, pg/mL 1.381 (1.123, 1.698) 0.32 0.105 9.5 0.0020
Heart rate per 5-bpm increase 1.045 (1.014, 1.083) 0.05 0.017 7.6 0.0059
EF per 5% decrease 60 1.110 (1.030, 1.196) 0.1 0.038 7.3 0.0068
QOL per 5-unit increase 50 1.045 (1.012, 1.079) 0.04 0.016 6.9 0.0087
Ischemic etiology 1.128 (0.931, 1.366) 0.12 0.098 1.5 0.2207
Myocardial infarction 1.085 (0.890, 1.323) 0.08 0.101 0.6 0.4229
Hosp indicates hospitalization; COPD, chronic obstructive pulmonary disease.
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Also, none of the previous analyses have included NT
pro-BNP, which may have altered the strength of renal
function as associated with outcome.
Log neutrophil count was also correlated to outcome in our
3 models. The association of neutrophil count and outcome
has been reported previously in HF with low EF37 and after
myocardial infarction,38 and increased neutrophil lifespan has
been described in this condition.39 This marker might reflect
the deleterious role of chronic inflammation in HF with
associated prothrombotic and proatherogenic effects.
Previous models have provided useful prognostic informa-
tion in HF. Although some of our independent factors are
similar to those identified in the CHARM overall popula-
tion,24 the CHARM trial included HF patients spanning the
full range of EF values, and the prognostic analysis did not
include laboratory parameters. The lack of laboratory values
is also true for the SEATTLE model, which was constructed
in low-EF HF only.40
Overall, the 3 models developed in the present study show
that a limited set of simple clinical, demographic, and
biological variables provides important information for the
association with all-cause mortality, cardiovascular morbid-
ity, or HF events. These models are based on a large sample
of patients with HF-PEF enrolled in I-PRESERVE with
documented inclusion criteria and on a long follow-up period.
They have been developed out of a large number of events
adjudicated by an end point committee based on predefined
criteria. Moreover, the consistency of the variables associated
with the 3 different outcomes suggests that these models are
robust.
The goodness of fit of our models to predict any individ-
ual’s risk of each outcome was also confirmed by the
consistency between predicted and observed rates of events
and its internal validity verified by C-statistic values. Simple
demographic, clinical, and biological data allow to group
patients in very low or very high risk groups. In particular,
NT-proBNP, age, previous HF hospitalization, and diabetes
mellitus are strongly correlated with outcome and should be
carefully taken into consideration when assessing risk in
HF-PEF. These factors could also enrich populations to be
studied in future trials with HF-PEF.
Limitations
The I-PRESERVE population was studied in the context of a
clinical trial with exclusion criteria. This population is there-
fore selective compared with patients with HF-PEF in clinical
practice. In particular, patients with moderate or severe renal
dysfunction were excluded from the trial. Also diabetes
mellitus was reported by investigators but no specific crite-
rion was used for the diagnosis of this important factor. The
study cohort was nearly exclusively White and therefore may
not be generalizable to other ethnicities.
Further, our model was built based on a subset of the total
population albeit a moderate but nonetheless substantial and
similar subgroup of 2563 patients for which the full set of
baseline variables was available. Moreover, after checking
the effect of the missing data by imputation and refitting the
models, the effect on the model estimates between the 2
cohorts were marginal and we therefore proceeded to use the
entire cohort with imputed data to report our final models.
Table 4. Upper Cutoff of Risk Score Septiles
Outcome
Septile of Risk
1st 2nd 3rd 4th 5th 6th 7th
Primary composite 29.72 33.09 36.16 39.12 42.19 46.00 65.09
All-cause mortality 42.09 46.01 49.54 52.83 56.36 60.44 83.84
HF composite 35.08 39.04 42.95 46.43 50.72 55.62 79.26
Figure 1. Kaplan–Meier curves of risk septiles for each
outcome.
Figure 2. Calibration of model selection by using Efron boot-
strap, with B200 resamples and 7 equally divided groups of
patients by 3-year survival probability. Fraction surviving (y-axis)
is from Kaplan–Meier estimates. Predicted survival (x-axis) is
from Cox proportional hazard model.
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Finally, the prognostic power of our models was not
validated in an independent cohort, though it is supported by
statistical techniques such as bootstrapping. Further valida-
tion should be performed in other populations.
Conclusion
We report models of associations for 3 important prespecified
outcomes in elderly patients with HF-PEF included in the
I-PRESERVE trial. We have identified a limited set of
demographic, clinical, and biological variables that provide
important and independent prognostic information and are
consistent across the 3 models developed. These models
allow the identification of a subgroup of patients at very high
risk of events and should be validated in existing data bases
and in future trials on HF-PEF.
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CLINICAL PERSPECTIVE
Recent surveys suggest that up to half of patients with heart failure have a preserved ejection fraction. In this condition,
which is associated with poor outcome and in particular a high rate of rehospitalization, identification of factors predicting
mortality or morbidity remains largely unexplored, in contrast to patients with heart failure and low ejection fraction. We
evaluated data from 4128 patients in the I-PRESERVE trial (Irbesartan in Heart Failure with Preserved Ejection Fraction
Study). We report an analysis identifying clinical, demographic, and biological factors associated with the primary end
point outcome (all-cause mortality or cardiovascular hospitalization), all-cause mortality, and heart failure death or
hospitalization. We found that log N-terminal pro–B-type natriuretic peptide, age, diabetes mellitus, previous hospitaliza-
tion for heart failure, ejection fraction, and other simple clinical or biological variables were associated with a more
unfavorable outcome. The models were able to identify subgroups of patients at very high and very low risk. Our analysis
provides new tools for the prognostic evaluation of heart failure with preserved ejection fraction and the factors that should
be taken into consideration when assessing the prognosis of patients with heart failure and preserved ejection fraction.
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Supplemental Material 
 
 
 
Figure. A: Hazard ratios by 5% groups of ejection fraction for each of the three 
outcomes. B: Hazard ratios by septiles of log NT-proBNP plasma level for eache of the 
three outcomes. C: Hazard ratios by groups of 10 units of estimated glomerular filtration 
rate (GFR) for the three outcomes. D: Hazard ratios by septiles of age for the three 
outcomes. 
 




